Cardiovascular effects of metyrapone treatment in patients with mild autonomous cortisol secretion: a secondary analysis

Clicks: 20
ID: 317083
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Steady

Ranked #231 of 449 articles by views in the journal of clinical endocrinology & metabolism

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 449 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
CONTEXT AND OBJECTIVE: Mild autonomous cortisol secretion (MACS) is associated with increased mortality, mainly because of cardiovascular disease. Here we investigated the effects of cortisol-lowering medical treatment on blood pressure regulation, cardiac fat depots, heart function and morphology, and other cardiovascular risk factors. DESIGN, SETTING AND INTERVENTION: In this secondary analysis of our prospective, open-label, single-center study at the Medical University of Vienna, we investigated 15 patients with MACS (12 females; age 59 [53-64] years) before and after 12 weeks of treatment with evening doses of metyrapone (500 mg at 6 p.m. and 250 mg at 10 p.m.). OUTCOME MEASURES AND METHODS: Cardiac fat stores, morphology and myocardial function were evaluated using cardiac magnetic resonance imaging and spectroscopy. Orthostatic blood pressure regulation was measured by standardized protocols. Lipidomics, renin-angiotensin-aldosterone-system activity and branched-chain amino acid (BCAA) concentrations were assessed. RESULTS: Mean supine systolic (137[121-139] vs 122[115-129] mmHg; p=0.041) and diastolic (89[80-93] vs 75[71-86] mmHg; p=0.045) blood pressure decreased after treatment in patients without changes in concomitant antihypertensive medication. Epicardial fat was lower at follow up compared to baseline (1032.70[894.23-1482.90] vs 929.37[736.12-1317.15]mm2; p=0.022). No changes in paracardial- and intramyocardial fat, as well as in cardiac function and morphology were observed. The aldosterone-to-angiotensin II ratio was lower at follow up (1.56[0.87-2.82] vs 1.21[0.98-1.92]; p=0.042) and alterations in lipid profiles, but not in BCAA levels were identified. CONCLUSIONS: Treatment with evening doses of metyrapone improved blood pressure and reduced epicardial adipose tissue.
Reference Key
openalex_W7164391582 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Helena Niziolek, Ivica Just, Clemens Baumgartner, Anna Tosin, Hansjörg Habisch, Paul Fellinger, Hannes Beiglböck, Michael Poledniczek, Luise Bellach, A Luger, Alexandra Kautzky‐Willer, S Trattnig, Maximilian Zeyda, Thomas Scherer, Marie Helene Schernthaner-Reiter, Florian W. Kiefer, Greisa Vila, Andreas A. Kammerlander, Tobias Madl, Michael Leutner, Martin Krššák, Michael Krebs, Peter Wolf
Are you one of these authors? Claim your profile
Journal the journal of clinical endocrinology & metabolism
Year 2026
DOI
10.1210/clinem/dgag228
URL
https://doi.org/10.1210/clinem/dgag228
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.